---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-035961"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:25:00.153745+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Unicycive Therapeutics FY2025 net loss $26.6M ($1.67/sh); OLC PDUFA date June 29, 2026

## Summary
- Net loss attributable to common holders: $26.6M ($1.67/sh) vs $37.8M ($5.65/sh) in FY2024.
- Cash, equivalents, securities $54.9M as of March 30, 2026; runway into 2027.
- FDA accepted OLC NDA resubmission; PDUFA target action date June 29, 2026.
- R&D expenses $9.1M (down from $20.0M); G&A $20.4M (up from $12.1M) due to commercial prep.
- Commercial readiness for potential OLC launch in 3Q26 ongoing.

## SEC filing metadata
- accession: 0001213900-26-035961
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/0001213900-26-035961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/ea0283942-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-035961
- JSON: https://secwatch.observer/filing/0001213900-26-035961.json
- Plain text: https://secwatch.observer/filing/0001213900-26-035961.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported the full year ended December 31, 2025 results: net income $26.6 million, EPS $1.67 per share of common stock.
  - Period: the full year ended December 31, 2025
  - Net income: $26.6 million
  - EPS: $1.67 per share of common stock
  - Result: reported results
  source text: Net loss attributable to common stockholders for the year ended December 31, 2025 was $26.6 million, or $1.67 per share of common stock, compared to a net loss attributable to common stockholders of $37.8 million, or $5.65 per share of common stock for the same period in 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/0001213900-26-035961-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.